| Description | VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor. |
| molecular weight | 459.64 |
| Molecular formula | C26H37NO4S |
| CAS | 914778-92-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 39 mg/mL (78.36 mM) |
| References | 1. Ludmila Gerber, Tania M. Welzel, Stefan Zeuzem. New therapeutic strategies in HCV: polymerase inhibitors. Liver International. 2013,33(s1): 85-92 2. Abdelrahman S. Mayhoub. Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorganic & Medicinal Chemistry. 2012, 20 (10): 3150-3161. 3. Debasis Dasa, Jian Honga, Shu-Hui Chena, et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry. 2011, 19(16): 4690-4703 4. Pierre L Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Informahealthcare. 2009, 19(2): 145-164 5. Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection |